Holen Sie sich die Stockscreener-App
2.885
2.68%
-0.105
Schlusskurs vom Vortag:
$2.99
Offen:
$3
24-Stunden-Volumen:
549.32K
Relative Volume:
2.13
Marktkapitalisierung:
$98.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-1.0186
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
-25.19%
1M Leistung:
-48.77%
6M Leistung:
-74.54%
1J Leistung:
-80.74%
1-Tages-Spanne:
$2.825
$3.3838
1-Wochen-Bereich:
$2.825
$3.91
52-Wochen-Spanne:
$2.825
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
2.885 | 98.90M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.17 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.14 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
625.24 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.86 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
270.21 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Lexeo stock hits 52-week low at $4.23 amid market challenges - MSN
Lexeo stock plunges to 52-week low at $3.42 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock plunges to 52-week low at $3.42 amid market challenges - Investing.com India
Lexeo Therapeutics CEO sells $19,090 in stock By Investing.com - Investing.com Nigeria
Lexeo Therapeutics chief medical officer sells $10,410 in stock By Investing.com - Investing.com Canada
Top Executives at Lexeo Therapeutics Cash In on Stock Sales! - TipRanks
Lexeo Therapeutics chief medical officer sells $10,410 in stock - Investing.com
Lexeo Therapeutics CEO sells $19,090 in stock - Investing.com India
Lexeo Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Lexeo Therapeutics CMO Sells Shares to Cover Tax Obligations - TradingView
SG Americas Securities LLC Makes New $72,000 Investment in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus Price Target from Brokerages - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of “Buy” from Brokerages - Defense World
Market Recap: Lexeo Therapeutics Inc (LXEO)’s Negative Momentum, Closing at 4.95 - The Dwinnex
Lexeo Therapeutics Inc (LXEO) Stock: A Look at the Analyst Recommendations - The News Heater
BlackRock, Inc. Expands Holdings with Lexeo Therapeutics Inc. Ac - GuruFocus.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
JPMorgan Chase & Co. Boosts Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
(LXEO) Trading Advice - Stock Traders Daily
Lexeo stock touches 52-week low at $4.76 amid market challenges - MSN
Leerink Partnrs Has Positive Outlook of LXEO FY2026 Earnings - Defense World
FY2026 EPS Estimate for Lexeo Therapeutics Raised by Analyst - MarketBeat
Lexeo Therapeutics’ (LXEO) Outperform Rating Reiterated at Royal Bank of Canada - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - MarketBeat
Barclays PLC Acquires 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus Target Price from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Lexeo stock plunges to 52-week low, hits $5.75 amid market challenges - Investing.com Nigeria
How to Take Advantage of moves in (LXEO) - Stock Traders Daily
Jane Street Group LLC Buys 8,918 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexeo Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Increases Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Geode Capital Management LLC Acquires 256,635 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Barclays PLC Buys 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Raised by State Street Corp - Defense World
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
BNP Paribas Financial Markets Increases Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| See Tai Sandi | Chief Development Officer |
Feb 19 '25 |
Sale |
4.41 |
1,486 |
6,558 |
53,889 |
| Adler Eric | Chief Medical Officer |
Feb 19 '25 |
Sale |
4.41 |
2,359 |
10,410 |
68,266 |
| Robertson Jenny | Chief Legal Officer |
Feb 19 '25 |
Sale |
4.41 |
2,101 |
9,272 |
57,899 |
2.40%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):